Does sorafenib inhibit imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants?
Sorafenib might be a promising anticancer agent for patients carrying KIT and PDGFRbeta gatekeeper mutations.
Anthropometry of the hand using the 2D:4D ratio is not a predictor of PCa.